Newsroom | 4525 results

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced the presentation of initial clinical data from the first participant dosed in its Phase 1/2 trial of EN-374 for the treatment of X-linked chronic granulomatous disease (X-CGD) at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15 in Boston. The data represent the first reported clini...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company’s previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, the single-cell multi-omics leader, today released data showing that its Targeted Single-Cell DNA+RNA Assay simultaneously resolves CRISPR edit co-occurrence, allelic zygosity, and downstream gene expression changes in individual cells of multiplex-engineered T cell populations, a capability legacy analytical methods cannot provide. The findings will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, taking place in Boston May 11-15. “We look forward to presenting at ASGCT on our lead investigational cell therapy AURN001, a potential first-in-cla...

SANTA ANA, Calif. & HUDDINGE, Sweden--(BUSINESS WIRE)--FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal stromal cells (MSC), today announced a global commercial launch resulting from their strategic collaboration. The offering consists of FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium and NextCell’s first commercial product, NextCell-Cord RUO, a research-use-...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome™ (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) programming platform that enables expansion into in vivo rejuvenation and reprogramming, today announced the appointment of Stefan Irion, MD, as chief scientific officer. Dr. Irion brings more than two decades of experience translating stem cell science into clinical...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts in the EL...

LOS ANGELES--(BUSINESS WIRE)--EarlyDiagnostics (EarlyDx) announced PNAS validation of its MethylScan™ platform for multi-disease detection from a single blood sample....

SYDNEY--(BUSINESS WIRE)--Integrant announced its CTC Formula, an AI Regenerative Matrix Engine, published in Chaos to Creation for scientific release....

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha approvato Jakafi XR™ (ruxolitinib) compresse a rilascio prolungato per il trattamento di pazienti adulti affetti da mielofibrosi (MF) intermedia o ad alto rischio; gli adulti affetti da policitemia vera (PV) che hanno avuto una risposta inadeguata o sono intolleranti alla idrossiurea; oltre ad adulti e bambini di età minima 12 anni con malattia da trapianto contro...